The agreement will lower the cost of certain drugs for asthma, some cancers, HIV and Type 2 diabetes, among other conditions.

On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for ...

Sciences announced an agreement with the U.S. government designed to reduce drug costs for Americans. “This agreement reflects a ...

As with any medicine, the MHRA will keep the safety and effectiveness of lenacapavir under close review. The Medicines and Healthcare products ...

Managing DirectorNews Is Out The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to talk about care, stigma and what living with HIV over the long-term means to ...

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy ...